Small-Cap Cancer Focused Theseus Pharmaceuticals Goes Privat

Small-Cap Cancer Focused Theseus Pharmaceuticals Goes Private For Over $3.90/Share In Cash - Theseus Pharmaceuticals (NASDAQ:THRX)

Theseus Pharmaceuticals Inc (NASDAQ: THRX) on Friday, has entered into a definitive merger agreement whereby Concentra Biosciences LLC will acquire Theseus for a price per share of between $3.90 and $4.05 in cash, consisting of a base cash price of $3.90 per share and an addi

Related Keywords

, Concentra Biosciences , Theseus Pharmaceuticals Inc , Theseus Pharmaceuticals , Pharmaceuticals Inc , Contingent Value Rights , Theseu Board , Tang Capital Partners ,

© 2025 Vimarsana